NO20075655L - Terapeutisk RNAI for respiratorisk virusinfeksjon - Google Patents

Terapeutisk RNAI for respiratorisk virusinfeksjon

Info

Publication number
NO20075655L
NO20075655L NO20075655A NO20075655A NO20075655L NO 20075655 L NO20075655 L NO 20075655L NO 20075655 A NO20075655 A NO 20075655A NO 20075655 A NO20075655 A NO 20075655A NO 20075655 L NO20075655 L NO 20075655L
Authority
NO
Norway
Prior art keywords
viral infection
respiratory viral
therapeutic rnai
rnai
therapeutic
Prior art date
Application number
NO20075655A
Other languages
English (en)
Norwegian (no)
Inventor
Qing Ge
Mukesh Kumar
James Anthony Mcswiggen
Original Assignee
Mdrna Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mdrna Inc filed Critical Mdrna Inc
Publication of NO20075655L publication Critical patent/NO20075655L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20075655A 2005-04-08 2007-11-06 Terapeutisk RNAI for respiratorisk virusinfeksjon NO20075655L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66994205P 2005-04-08 2005-04-08
PCT/US2006/013374 WO2006110688A2 (en) 2005-04-08 2006-04-07 Rnai therapeutic for respiratory virus infection

Publications (1)

Publication Number Publication Date
NO20075655L true NO20075655L (no) 2007-11-13

Family

ID=37087607

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075655A NO20075655L (no) 2005-04-08 2007-11-06 Terapeutisk RNAI for respiratorisk virusinfeksjon

Country Status (10)

Country Link
US (1) US20100254945A1 (ko)
EP (1) EP1874802A2 (ko)
JP (1) JP2008535496A (ko)
KR (1) KR20070118703A (ko)
CN (1) CN101184839A (ko)
AU (1) AU2006235364A1 (ko)
CA (1) CA2603842A1 (ko)
NO (1) NO20075655L (ko)
NZ (1) NZ563845A (ko)
WO (1) WO2006110688A2 (ko)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297786B2 (en) 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
WO2007017759A2 (en) * 2005-03-31 2007-02-15 Ronen Kahana Creating poultry and other animals resistant to viral disease
EP2125024B1 (en) 2007-03-23 2013-02-13 TO-BBB Holding B.V. Targeted intracellular delivery of antiviral agents
WO2008128176A1 (en) * 2007-04-12 2008-10-23 Nucleonics, Inc. Influenza polynucleotides, expression constructs, compositions, and methods of use
EP2152316A4 (en) * 2007-04-26 2011-03-23 Quark Pharmaceuticals Inc THERAPEUTIC DELIVERY OF INHIBITORY NUCLEIC ACID MOLECULES IN THE RESPIRATORY SYSTEM
WO2008138066A1 (en) * 2007-05-15 2008-11-20 Johnson & Johnson Research Pty Limited Suppression of viruses involved in respiratory infection or disease
CN101918558B (zh) * 2007-05-16 2016-12-07 Mat马耳他先进技术有限公司 流感的治疗及预防
US20100273156A1 (en) 2007-05-31 2010-10-28 Becton, Dickinson And Company Sequences and methods for detecting influenza a and influenza b virus
CN105125572A (zh) 2009-12-18 2015-12-09 箭头研究公司 用于治疗hsf1相关疾病的有机组合物
WO2012053741A2 (ko) 2010-10-22 2012-04-26 성균관대학교산학협력단 Rna 간섭을 유도하는 핵산 분자 및 그 용도
MX356426B (es) * 2011-04-04 2018-05-29 Univ Iowa Res Found Metodos para mejorar inmunogenicidad de vacuna.
WO2013012835A2 (en) * 2011-07-18 2013-01-24 Oregon Health & Science University Sirna useful in the treatment of flavivirus infection
EP3521432A1 (en) 2011-09-02 2019-08-07 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat hsf1-related diseases
DK2853597T3 (en) * 2012-05-22 2019-04-08 Olix Pharmaceuticals Inc RNA INTERFERENCE-INducing NUCLEIC ACID MOLECULES WITH CELL PENETENING EQUIPMENT AND USE THEREOF
BR112015009103A2 (pt) * 2012-10-23 2017-07-04 Harrisvaccines Inc método para proteger um animal invertebrado aquático contra o vírus da mionecrose infecciosa (imnv), método para produzir um composição e composição
CN103966212A (zh) * 2013-02-06 2014-08-06 霍晋 A型流感病毒NP基因有干扰作用的siRNA序列的设计及应用
US20140289881A1 (en) * 2013-03-14 2014-09-25 Commonwealth Scientific And Industrial Research Organisation Double-stranded rna
CN108699556B (zh) 2015-11-16 2023-02-17 奥利克斯医药有限公司 使用靶向myd88或tlr3的rna复合物治疗老年性黄斑变性
CN108779464B (zh) 2016-02-02 2022-05-17 奥利克斯医药有限公司 使用靶向angpt2和pdgfb的rna复合物治疗血管生成相关性疾病
US10358648B2 (en) 2016-02-02 2019-07-23 Olix Pharmaceuticals, Inc. Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1
CA3014776A1 (en) * 2016-03-02 2017-09-08 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
WO2021201996A1 (en) * 2020-02-14 2021-10-07 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against respiratory viruses and methods of using the same
US11339392B2 (en) 2016-03-02 2022-05-24 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
EP3443093A4 (en) 2016-04-11 2020-01-01 Olix Pharmaceuticals, Inc. TREATMENT OF IDIOPATHIC LUNG FIBROSIS WITH RNA COMPLEXES TARGETED AGAINST THE TISSUE GROWTH FACTOR
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
WO2018146557A2 (en) 2017-02-10 2018-08-16 Dong Ki Lee Long double-stranded rna for rna interference
CN111201330A (zh) * 2017-10-09 2020-05-26 汉诺威医学院 用于人类呼吸道合胞病毒（hrsv）的诊断和疗法
CA3096938A1 (en) * 2018-04-10 2019-10-17 Ottawa Hospital Research Institute Microrna-based compositions and methods used in disease treatment
US11702709B2 (en) * 2021-02-09 2023-07-18 Pathogendx, Inc. Combinatorial microarray assay for clade variant detection
CN115120608A (zh) * 2021-03-26 2022-09-30 圣诺生物医药技术(苏州)有限公司 一种siRNA药物、药物组合物、siRNA-小分子药物偶联物及其应用
WO2024026418A1 (en) * 2022-07-28 2024-02-01 New York University Targeting long non-coding rna chromr in interferon-mediated inflammation in humans

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4876187A (en) * 1985-12-05 1989-10-24 Meiogenics, Inc. Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences
US5011769A (en) * 1985-12-05 1991-04-30 Meiogenics U.S. Limited Partnership Methods for detecting nucleic acid sequences
US5403711A (en) * 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
US5185243A (en) * 1988-08-25 1993-02-09 Syntex (U.S.A.) Inc. Method for detection of specific nucleic acid sequences
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5573907A (en) * 1990-01-26 1996-11-12 Abbott Laboratories Detecting and amplifying target nucleic acids using exonucleolytic activity
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
WO1995014106A2 (en) 1993-11-17 1995-05-26 Id Biomedical Corporation Cycling probe cleavage detection of nucleic acid sequences
JP3175110B2 (ja) 1994-02-07 2001-06-11 オーキッド・バイオサイエンシーズ・インコーポレイテッド リガーゼ／ポリメラーゼ媒体された単一ヌクレオチド多型のジェネティックビットアナリシスおよび遺伝子解析におけるその使用
DE69738687D1 (de) * 1996-04-12 2008-06-26 Phri Properties Inc Sonden, kits und assays
US6037130A (en) 1998-07-28 2000-03-14 The Public Health Institute Of The City Of New York, Inc. Wavelength-shifting probes and primers and their use in assays and kits
US20030087851A1 (en) * 1999-01-20 2003-05-08 Biozak, Inc. Pharmaceutical composition for treating or preventing influenza, and novel oligonucleotide
US6277607B1 (en) * 1999-05-24 2001-08-21 Sanjay Tyagi High specificity primers, amplification methods and kits
EP1081496A1 (en) * 1999-08-31 2001-03-07 Becton, Dickinson and Company Flow-through assay for visually detecting the presence of influenza A and B
EP1546344A4 (en) * 2002-09-18 2007-10-03 Isis Pharmaceuticals Inc EFFICIENT REDUCTION OF TARGET RNA USING OLIGOMERIC COMPOUNDS WITH SINGLE AND DOUBLE STRAPS
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
WO2004028471A2 (en) * 2002-09-28 2004-04-08 Massachusetts Institute Of Technology Influenza therapeutic
US9486070B2 (en) 2012-10-10 2016-11-08 Stirworks Inc. Height-adjustable support surface and system for encouraging human movement and promoting wellness

Also Published As

Publication number Publication date
WO2006110688A3 (en) 2008-01-10
NZ563845A (en) 2010-09-30
CN101184839A (zh) 2008-05-21
US20100254945A1 (en) 2010-10-07
WO2006110688A2 (en) 2006-10-19
KR20070118703A (ko) 2007-12-17
CA2603842A1 (en) 2006-10-19
AU2006235364A1 (en) 2006-10-19
JP2008535496A (ja) 2008-09-04
EP1874802A2 (en) 2008-01-09
WO2006110688A9 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
NO20075655L (no) Terapeutisk RNAI for respiratorisk virusinfeksjon
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
MA32634B1 (fr) Polytherapie destinee a traiter une infection par le vhc
NO20045247L (no) Nukleosidderivater for behandling av hepatitt C-virusinfeksjon
ATE512976T1 (de) Hemmer des hepatitis-c-virus
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
EA202190473A3 (ru) Противовирусная терапия
HRP20070435A9 (en) Tricyclic-nucleoside compounds for treating viral infections
EA200900298A1 (ru) Ингибиторы вируса гепатита с
EA201071315A1 (ru) Ингибиторы протеазы вируса гепатита с
NZ593111A (en) Antibacterial compounds
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20062146L (no) Nukleosidforbindelser for behandling av virusinfeksjoner
EP3812372A3 (en) 7-heterocyclyl substituted sancycline derivatives for treating bacterial, viral and parasitic infections (e.g. malaria) or inflammatory diseases
SG163517A1 (en) Antiviral compounds and methods
MY141003A (en) Materials and methods for treating viral infections with a cysteamine compound
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
NO20065320L (no) Imidazolderivater anvendt som tafiainhibitorer
TW200633995A (en) Andrographolide derivatives to treat viral infections
NO20083245L (no) Sykliske antimikrobielle peptider
EA200970586A1 (ru) Антитела к цитомегаловирусу человека (hcmv)
MXPA05010440A (es) Amidas del acido isoquinolina-5-sulfonico como inhibidores de la akt (proteina quinasa b).
EA201170484A1 (ru) Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application